Author

W. Jochum

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

A.-K. Jochum· 2 shared L. Flatz· 2 shared A. Christiansen· 1 shared A. Ferguson· 1 shared A. Fleischmann· 1 shared A. Garofoli· 1 shared A. Muenster-Kuehnel· 1 shared A. Obenauf· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPathology

A.-K. Jochum

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19

N. A. Lengacher, J. J. Tomlinson, A.-K. Jochum, J. Franz, O. Hasan Ali, L. Flatz, W. Jochum, J. Penninger, aSCENT-PD Investigators, C. Stadelmann-Nessler, J. M. Woulfe, M. G. Schlossmacher

This study examines neuropathological changes in the olfactory bulb and tract of COVID-19 patients, finding no significant inflammation but age-related decline in anti-CD68 reactivity and mild increases in phospho-Syn and phospho-tau signals in affected brains.

bioRxiv · Dec 18, 2023Pathology

Tumor sialylation controls effective anti-cancer immunity in breast cancer

S. Mereiter, G. Jonsson, T. Oliveira, J. Helm, D. Hoffmann, M. Abeln, A.-K. Jochum, W. Jochum, M. J. Kellner, M. Feith, V. Tkalec, K. Wasilewska, J. Jiao, L. Emsenhuber, F. Holstein, , J. M. Penninger

This study shows that tumor sialylation suppresses anti-cancer immunity in breast cancer by altering immune cell interactions and checkpoint ligands, and that inhibiting sialylation enhances immune response and therapy effectiveness.

bioRxiv · Sep 20, 2023 · PreprintCancer Biology

The Genomic Landscape of Prostate Cancer Brain Metastases

A. Rodriguez, J. Gallon, D. Akhoundova, S. Maletti, A. Ferguson, J. Cyrta, U. Amstutz, A. Garofoli, V. Paradiso, S. Tomlins, E. Hewer, V. Genitsch, A. Fleischmann, E. J. Rushing, R. Grobholz, , M. A. Rubin

This study identifies genomic alterations in prostate cancer brain metastases, highlighting mutations in NF1 and RICTOR and DNA homologous repair defects as potential drivers.

bioRxiv · May 12, 2020 · PreprintCancer Biology

High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification

Y. J. Zhu, T. Weiss, Q. Zhang, R. Sun, B. Wang, Z. Wu, Q. Zhong, X. Yi, H. Gao, X. Cai, G. Ruan, T. Zhu, C. Xu, S. Lou, X. Yu, , T. Guo

This study develops a proteomic workflow for FFPE tissues to stratify prostate cancer and DLBCL samples, identifying MPO as a prognostic marker and showing FFPE's utility for biomarker discovery.

bioRxiv · Jun 11, 2019Biochemistry